样式: 排序: IF: - GO 导出 标记为已读
-
Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-28 Kazuaki Harada,Satoshi Yuki,Yasuyuki Kawamoto,Takeaki Nakamura,Shiho Kaneko,Koichi Ishida,Naoya Sakamoto,Yoshito Komatsu
The NeoRAS phenomenon is defined as the conversion of tumor RAS status from mutant-type (MT) to wild-type (WT) after systemic chemotherapy in metastatic colorectal cancer (mCRC). Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, is effective in patients with RAS WT mCRC but ineffective in those with RAS MT mCRC; however, its outcome in patients with NeoRAS WT mCRC is unclear. Herein
-
Current role of PSMA-PET imaging in the clinical management of prostate cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-24 Alexander Georgakopoulos,Aristotle Bamias,Sophia Chatziioannou
Despite the developments of the last few years, metastatic castration-resistant prostate cancer (PC) remains a deadly disease. Until recently, almost all guidelines recommended magnetic resonance imaging (MRI) or computed tomography (CT) for the initial staging and local/systematic recurrence. Positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) at
-
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-22 Rasha Aboelhassan,Mohamed Emam Sobeih,Mohamed Alm El-Din,Ramy R Ghali,Ibtessam Saad El-Din,Ola Khorshid,Mohsen Mokhtar,Ahmed Magdy Rabea,Abdelaziz Belal,Hamdy A Azim,Mohamed Abdullah,Tamer Elnahas,Hesham Tawfik,Sherif Abdelwahab,Amr Abdelaziz Elsaid,Tarek Hashem,Mohamed Mancy,Heba Farag
Background Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We present findings on treatment patterns and their associated survival outcomes in patients with stage III NSCLC from the Egypt subset of the KINDLE global real-world study conducted across countries from Asia, Middle East, Africa, and Latin America
-
Clinical practice in prostate PET imaging. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-22 Sean J Huls,Brian Burkett,Eric Ehman,Val J Lowe,Rathan M Subramaniam,A Tuba Kendi
Positron emission tomography (PET) imaging in prostate cancer has advanced significantly in the past decade with prostate cancer targeted radiopharmaceuticals now playing a growing role in diagnosis, staging, and treatment. This narrative review focuses on the most commonly used PET radiopharmaceuticals in the USA: prostate-specific membrane antigen (PSMA), fluciclovine, and choline. 18F-fluorodeoxyglucose
-
Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-22 Gaofeng Zhu,Hongfu Cai,Zhiwei Zheng
Objective Cemiplimab combined with chemotherapy has emerged as a promising treatment option for advanced non-small cell lung cancer (NSCLC). Accordingly, this study has been conducted to evaluate the cost-effectiveness of this combination therapy in comparison to chemotherapy alone from the perspective of the United States healthcare system. Methods The present study is based on a partitioned survival
-
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-22 Gwo Yaw Ho,Cassandra J Vandenberg,Ratana Lim,Elizabeth L Christie,Dale W Garsed,Elizabeth Lieschke,Ksenija Nesic,Olga Kondrashova,Gayanie Ratnayake,Marc Radke,Jocelyn S Penington,Amandine Carmagnac,Valerie Heong,Elizabeth L Kyran,Fan Zhang,Nadia Traficante,,Ruby Huang,Alexander Dobrovic,Elizabeth M Swisher,Orla McNally,Damien Kee,Matthew J Wakefield,Anthony T Papenfuss,David D L Bowtell,Holly E Barker
Background Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinum-refractory disease. Objectives To determine the potential of anti-microtubule agent (AMA) therapy (paclitaxel, vinorelbine and eribulin) in platinum-resistant
-
Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-22 Ying-Tao Lin,Chong-Chong Zhou,Kai Xu,Meng-Die Zhang,Xin Li
Background This study evaluated the cost-effectiveness of serplulimab plus chemotherapy versus chemotherapy alone in treating advanced/metastatic esophageal squamous cell carcinoma (ESCC) within the Chinese health care system. Methods A partitioned survival model based on ASTRUM-007 trial patient characteristics was developed. Efficacy, safety, and medical/economic data were obtained from the trial
-
Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-13 Yuzhong Chen,Yuanjian Shi,Hanlin Ding,Yipeng Feng,Te Zhang,Yingkuan Liang,Hui Wang,Xuming Song,Bing Chen,Wenjie Xia,Qixing Mao,Bo Shen,Lin Xu,Gaochao Dong,Feng Jiang
Background The profile of immune-related adverse events (irAEs) due to programmed death-1 (PD-1) inhibitors-based combination therapy in advanced non-small cell lung cancer (NSCLC) and its relationship with survival have not been fully described. Objective Designed to capture the spectrum of irAEs and explore the association between irAEs and clinical outcomes in patients with NSCLC. Design This retrospective
-
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-10 Yuan Yuan,Colt Egelston,Oscar Colunga Flores,Shyambabu Chaurasiya,David Lin,Helen Chang,Leslie Mi Ok Chong,Amanda Seiz,Monil Shah,W Hans Meisen,Aileen Tang,Norma Martinez,Wichanee Pickett,Mireya Murga,Susan E Yost,Daphne Stewart,Jianying Zhang,Nicholas Ede,Badri Modi,Jonathan Kessler,Jamie Rand,Yuman Fong
Prognosis of metastatic triple negative breast cancer (mTNBC) remains poor despite recent advances in therapeutic options. Trastuzumab deruxtecan (T-DXd) has shown promising efficacy in patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer, which is defined by immunohistochemistry (IHC) 1+ or 2+ and lack of HER2 amplification by fluorescence in situ hybridization (FISH) testing
-
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer? Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-11-10 Chii Yang Kuah,Robert Monfries,Matteo Quartagno,Michael J Seckl,Ehsan Ghorani
Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown. Focusing on anti-PD1 agents nivolumab and pembrolizumab in the context of non-small cell lung cancer, we argue that several lines of evidence suggest
-
Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-31 Xiongwen Yang,Yi Xiao,Yubin Zhou,Huiyin Deng,Zihao Yuan,Longyan Dong,Jun Lan,Hao Hu,Jian Huang,Shaohong Huang
Background To date, no specific studies have reported the use of dynamic serum tumor markers (STMs) as prognostic factors in patients with advanced non-small-cell lung cancer (NSCLC) who receive first-line immunotherapy. Therefore, it is unclear whether STMs can be used as a prognostic factor for first-line immunotherapy in advanced NSCLC. Objectives To elucidate the role of STMs in monitoring immunotherapy
-
Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-31 Jui Wan Loh,Abner Herbert Lim,Jason Yongsheng Chan,Yoon-Sim Yap
Background Recently, HER2-negative breast cancers have been reclassified by protein expression into 'HER2-low' and 'HER2-zero' subgroups, but the consideration of HER2-low breast cancer as a distinct biological subtype with differing prognoses remains controversial. By contrast, non-neutral ERBB2 copy number alteration (CNA) status is associated with inferior survival outcomes compared to ERBB2 CNA-neutral
-
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-24 Qingyan Liu,Rong Li,Lingling Li,Gaokun Wang,Shiyu Ji,Xuan Zheng,Xiaodong Jia,Haitao Tao,Yi Hu
Background The efficacy of anti-programmed cell death (PD)-1 monotherapy in advanced hepatocellular carcinoma (aHCC) is limited, and combination therapy with lenvatinib and pembrolizumab has shown promising results. However, comparative studies between immune monotherapies and combination therapies are lacking. Objectives To investigate the efficacy and safety of anti-PD-1 monotherapy (PD-1) and anti-PD-1
-
Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-24 Huijuan Li,Hedong Han,Chuling Li,Ranpu Wu,Zhaofeng Wang,Yimin Wang,Ping Zhan,Tangfeng Lv,Fang Zhang,Yong Song,Hongbing Liu
Objectives Several randomized controlled trials (RCTs) indicated that first-line programmed cell death protein-1/death-ligand 1 inhibitors plus chemotherapy (PD-1/PD-L1 + chemo) led to survival benefits in extensive-stage small-cell lung cancer (ES-SCLC) compared with platinum-based chemotherapy. This study aims to identify the optimal PD-1/PD-L1 + chemo combination strategy. Methods We included RCTs
-
Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-24 Géraldine Lens,Niloefar Ahmadi Bidakhvidi,Vincent Vandecaveye,Steven Grauwels,Annouschka Laenen,Wies Deckers,Ronald Peeters,Raphaëla C Dresen,Jeroen Dekervel,Chris Verslype,Kristiaan Nackaerts,Paul M Clement,Eric Van Cutsem,Michel Koole,Karolien Goffin,Koen Van Laere,Christophe M Deroose
Background Somatostatin receptor (SSTR) positron emission tomography (PET) is a cornerstone of neuroendocrine tumor (NET) management. Hybrid PET/magnetic resonance imaging (MRI) is now available for NET-imaging, next to PET/computed tomography (CT). Objectives To determine whether CT or MRI is the best hybrid partner for [68Ga]Ga-DOTATATE PET. Design Monocentric, prospective study. Methods Patients
-
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-24 Li-Na He,Tao Chen,Sha Fu,Yongluo Jiang,Xuanye Zhang,Chen Chen,Wei Du,Linfeng Luo,Anlin Li,Yixing Wang,Hui Yu,Yixin Zhou,Yuhong Wang,Yunpeng Yang,Yan Huang,Hongyun Zhao,Wenfeng Fang,Li Zhang,Shaodong Hong
Background For Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1), measuring up to two target lesions per organ is an arbitrary criterion. Objectives We sought to compare response assessment using RECIST1.1 and modified RECIST1.1 (mRECIST1.1, measuring the single largest lesion per organ) in advanced non-small cell lung cancer (aNSCLC) patients undergoing anti-PD-1/PD-L1 monotherapy
-
PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-17 Langbiao Liu,Lei Niu,Xue Zheng,Fei Xiao,Huaibo Sun,Wei Deng,Jun Cai
Background The programed death ligand-1 combined positive score (PD-L1 CPS), the only FDA-approved biomarker for immune checkpoint inhibitor therapy in gastric cancer (GC) patients, is an important but imperfect predictive biomarker. The molecular characteristics of tumors that influence the PD-L1 CPS are largely unknown and would be helpful for screening patients who would benefit from immunotherapy
-
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-14 Youwen Zhu,Kun Liu,Hong Zhu,Hui Cao,Yangying Zhou
Background Recently, several new first-line immune checkpoint inhibitors (ICIs) plus chemotherapy have been approved for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, direct comparisons between first-line treatments are lacking. Therefore, we indirectly compared the efficacy and safety of specific treatment strategies to inform physicians' and patients' clinical decisions
-
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-11 Mingxia Jiang,Bin Shao,Donggui Wan,Jiaxuan Liu,Maiyue He,Yue Chai,Die Sang,Jiayu Wang,Fei Ma,Ying Fan,Peng Yuan,Binghe Xu,Qiao Li
Background The relative lack of specifically targeted agents for HER2-negative metastatic breast cancer (MBC) makes the need for new agents or combination therapies to maximize clinical benefit while reducing toxicity critical. Objectives To retrospectively analyze the efficacy and safety of eribulin combined with antiangiogenic drugs in the treatment of Chinese women with HER2-negative MBC. Methods
-
CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-11 Dragica Pavlovic,Danijela Niciforovic,Dragana Papic,Katarina Milojevic,Marina Markovic
Breast cancer is characterized by the uncontrolled proliferation of breast cells, with a high incidence reported in 2020 to have affected over 2 million women. In recent years, the conventional methods of treating breast cancer have involved radiotherapy and chemotherapy. However, the emergence of CDK4/6 inhibitors has shown potential as a promising cancer therapy. Cyclin-dependent kinases (CDK) inhibitors
-
Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-10-11 Jinglong Huang,Caifeng Gong,Aiping Zhou
Although immune checkpoint inhibitors (ICIs) have greatly improved the prognosis of some cancer patients, the majority still fail to respond adequately, and the available biomarkers cannot reliably predict drug efficacy. The gut microbiota has received widespread attention among the various intrinsic and extrinsic factors contributing to drug resistance. As an essential regulator of physiological function
-
Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-30 Zuzana Bielcikova,Lukas Werner,Jan Stursa,Vladimir Cerny,Ludmila Krizova,Jan Spacek,Stanislav Hlousek,Michal Vocka,Olga Bartosova,Michal Pesta,Katarina Kolostova,Petr Klezl,Vladimir Bobek,Jaroslav Truksa,Sona Stemberkova-Hubackova,Lubos Petruzelka,Pavel Michalek,Jiri Neuzil
Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable
-
Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-29 Hyehyun Jeong,Sung-Bae Kim
In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of
-
Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-29 Bernhard Doleschal,Patrick Kirchweger,Simon Schwendinger,Alexander Kupferthaler,Jonathan Burghofer,Gerald Webersinke,Emina Jukic,Helwig Wundsam,Matthias Biebl,Andreas Petzer,Holger Rumpold
Background Serial analysis of circulating tumor DNA (ctDNA) levels is a promising tool for both relapse prediction in the curative setting, as well as predicting clinical benefit from systemic treatment in metastasic colorectal cancer (mCRC). Most data in this context are derived from treatment naive patients. Objective To predict progressive disease (PD) as early as possible through monitoring of
-
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-28 Mattea Reinisch,Simona Bruzas,Jennifer Spoenlein,Satyendra Shenoy,Alexander Traut,Hakima Harrach,Ouafaa Chiari,Efsthatia Cremer,Beyhan Ataseven,Lars Gubelt,Sherko Kuemmel
Background Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer centre in Germany. Methods Data from patients who had received sacituzumab govitecan as treatment for mTNBC
-
External validation of the first prognostic nomogram for older adults with cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-28 Yu Ling Tay,Whee Sze Ong,Sherilyn Zi Hui Liew,Anupama Roy Chowdhury,Johan Chan,Mothi Babu Ramalingam,Tanujaa Rajasekaran,Tira J Tan,Lalit Krishna,Olive Lai,Agnes Lai Yin Chow,Simon Chen,Ravindran Kanesvaran
Background The geriatric oncology population tends to be complex because of multimorbidity, functional and cognitive decline, malnutrition and social frailty. Prognostic indices for predicting survival of elderly cancer patients to guide treatment remain scarce. A nomogram based on all domains of the geriatric assessment was previously developed at the National Cancer Centre Singapore (NCCS) to predict
-
Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-28 Mauricio Fernando Ribeiro,Hagit Peretz Soroka,Zainab Bhura,Ian Hirsch,Jay Wunder,Peter Ferguson,Kim Tsoi,Savtaj Brar,Rebecca Gladdy,Carol Swallow,Peter Chung,Charles Catton,Philip Wong,Geoffrey Watson,Albiruni Ryan Abdul Razak,Abha A Gupta,David Shultz
Background Radiation-induced sarcomas (RIS) tend to have aggressive behaviour and because of their rarity, the most appropriate management for these malignancies is uncertain. Objectives Using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database, a national sarcoma registry, we aimed to investigate prognostic factors and outcomes for RIS. Design Retrospective study of RIS patients
-
Role of immunotherapy in chondrosarcoma: A case report and review of the literature. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-21 Adam J Cohen-Nowak,Danielle B Dressler,Adam Rock,Katherine Mojica,Doni Woo,Lee M Zuckerman,Warren Chow,Mark Agulnik
Chondrosarcomas (CSs) consist of a heterogenous group of primary bone cancers arising from malignant cells which produce cartilaginous matrix. As the second most common primary bone cancer, CS are often resistant to systemic chemotherapy due to poor vascularization, slow proliferation, and expression of multidrug-resistant pumps. Immune checkpoint inhibitors have transformed the field of oncology and
-
Ovarian cancer in the older patient: where are we now? What to do next? Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-16 Frédérique Rousseau,Florence Ranchon,Christophe Bardin,Naoual Bakrin,Vincent Lavoué,Leila Bengrine-Lefevre,Claire Falandry
In recent years, major advances have been made toward the individualization of epithelial ovarian cancer care, leading to an overall improvement of patient outcomes. However, real-life data indicate that the oldest populations do not benefit from this, due to aspects related to cancer (more aggressive histopathological features), treatment (i.e. frequently suboptimal), and the host (increased toxicities
-
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-15 Robert B Cameron,Jacobi B Hines,Valter Torri,Luca Porcu,Jessica Donington,Christine M Bestvina,Everett Vokes,James M Dolezal,Alessandra Esposito,Marina C Garassino
Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete pathologic response has been shown to be an appropriate surrogate endpoint for clinical outcomes, such as event-free survival or overall survival, in
-
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-15 Talia Golan,Raffaella Casolino,Andrew V Biankin,Pascal Hammel,Kristen D Whitaker,Michael J Hall,Douglas L Riegert-Johnson
Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line platinum-based chemotherapy and maintenance therapy with the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib following at least 16 weeks of first-line platinum-based chemotherapy without disease progression. Germline
-
Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-15 Maria Luisa Gasparri,Sara Albasini,Marta Truffi,Karin Favilla,Barbara Tagliaferri,Francesca Piccotti,Daniela Bossi,Giulia Armatura,Arianna Calcinotto,Corrado Chiappa,Francesca Combi,Annalisa Curcio,Angelica Della Valle,Guglielmo Ferrari,Secondo Folli,Matteo Ghilli,Chiara Listorti,Stefano Mancini,Peter Marinello,Simone Mele,Anna Pertusati,Manuela Roncella,Lorenzo Rossi,Francesca Rovera,Silvia Segattini
Background Systemic inflammatory markers draw great interest as potential blood-based prognostic factors in several oncological settings. Objectives The aim of this study is to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and pan-immune-inflammation value (PIV) predict nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in node-positive (cN+) breast cancer (BC) patients
-
Navigating the challenges of invasive pulmonary aspergillosis in lung cancer treatment: a propensity score study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-14 Chin-Wei Kuo,Chien-Yu Lin,Sheng-Huan Wei,Yun-Tse Chou,Chian-Wei Chen,Jeng-Shiuan Tsai,Po-Lan Su,Chien-Chung Lin
Background Invasive pulmonary aspergillosis (IPA) can negatively impact cancer patients' survival. It remains uncertain whether IPA's impact on patient outcomes varies by treatment approach in advanced lung cancer. Objectives To explore the association between IPA and outcomes in patients with advanced lung cancer receiving different treatments. Design A retrospective cohort study. Methods We enrolled
-
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-13 Hiromi Matsumoto,Kohei Somekawa,Nobuyuki Horita,Suguru Ueda,Megumi Kaneko,Ayami Kaneko,Nobuhiko Fukuda,Ami Izawa,Chisato Kamimaki,Katsushi Tanaka,Kota Murohashi,Hiroaki Fuji,Yoichi Tagami,Ayako Aoki,Keisuke Watanabe,Yu Hara,Nobuaki Kobayashi,Takeshi Kaneko
Background Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a new ICI combination therapy, and its efficacy has been reported in various types of cancer. However, the safety profile of DT remains unclear, especially considering rare adverse events (AEs). Objective We aimed to assess the
-
Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-13 Camille Ardin,Sarah Humez,Vincent Leroy,Alexandre Ampere,Soraya Bordier,Fabienne Escande,Amélie Turlotte,Luc Stoven,David Nunes,Alexis Cortot,Clément Gauvain
Background The optimal duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains to be determined. Treatment durations in cornerstone phase 3 clinical trials vary between a fixed 2-year duration and pursuit until disease progression. Clinical practices may thus differ according to the attending physician. Objectives Here we provide
-
Long-term outcomes in a retrospective cohort of patients with rectal cancer with complete response after total neoadjuvant therapy: a propensity-score weighted analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-08 Jingwen Wang,Lijie Zhang,Minghe Wang,Jing Zhang,Yaqi Wang,Juefeng Wan,Guichao Li,Hui Zhang,Yan Wang,Ruiyan Wu,Zhiyuan Zhang,Xinxiang Li,Ye Xu,Ji Zhu,Lijun Shen,Fan Xia,Zhen Zhang
Background The watch-and-wait (W&W) strategy is a novel treatment option for patients with rectal cancer who have a strong desire for organ preservation. The study aimed to explore the long-term outcomes of the W&W strategy in a large cohort of rectal cancer patients who achieved a clinical complete response (cCR) after consolidation total neoadjuvant therapy (TNT), and to compare with patients who
-
Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-07 Vahid Yaghoubi Naei,Pritam Bordhan,Fatemeh Mirakhorli,Motahare Khorrami,Jesus Shrestha,Hojjatollah Nazari,Arutha Kulasinghe,Majid Ebrahimi Warkiani
Over the past decade, the detection and analysis of liquid biopsy biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced significantly. They have received recognition for their clinical usefulness in detecting cancer at an early stage, monitoring disease, and evaluating treatment response. The emergence of liquid biopsy has been a helpful development, as it
-
Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-09-07 Pauline Parent,Gautier Marcq,Sola Adeleke,Anthony Turpin,Stergios Boussios,Elie Rassy,Nicolas Penel
Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success of the ICI strategy alone or in combination with chemotherapy or targeted therapies. In addition, some patients experience potentially severe adverse events with limited
-
Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-31 Chance H Bloomer,Elena Gavrila,Kimberly M Burcher,John M Kalada,Mark J Chang,Rediet R Gebeyehu,Elsabeth Asare,Lara M Khoury,Rebecca Kinney,Bart Frizzell,Christopher A Sullivan,Paul M Bunch,Mercedes Porosnicu
Immunotherapy with PD-1 inhibitors monotherapy or combined with chemotherapy comprises the first-line palliative treatment for patients with recurrent or metastatic head and neck squamous cell cancers (R/M HNSCC). The established survival advantage among responders is overshadowed by the high percentage of patients failing the standard PD-1 inhibitor-based treatments. Salvage therapies are direly needed
-
Atezolizumab-induced subacute cerebellar ataxia in a patient with extensive-stage small cell lung cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-31 Chun-Chia Chen,Kuan-Hua Tseng,Kuan-Lin Lai,Chi-Lu Chiang
Recently, immune checkpoint inhibitors (ICIs) have become the standard treatment option for patients with lung cancer, including small cell lung cancer (SCLC). ICI-induced neurological immune-related adverse events are rare and exhibit diverse clinical manifestations, often leading to missed or delayed diagnosis. Herein, we report the case of a patient with extensive-stage SCLC who received atezolizumab
-
The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-31 Durgesh Wankhede,Sandeep Grover,Paul Hofman
Background Tumor mutation burden (TMB) has been validated as a predictive biomarker for immunotherapy response and survival in numerous cancer types. Limited data is available on the inherent prognostic role of TMB in early-stage tumors. Objective To evaluate the prognostic role of TMB in early-stage, resected non-small cell lung cancer (NSCLC). Design Systematic review and meta-analysis of pertinent
-
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-31 Yang-Si Li,Guang-Ling Jie,Yi-Long Wu
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression
-
Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-31 Nicolas Penel,Coralie Cantarel,Claire Chemin-Airiau,Françoise Ducimetiere,François Gouin,François Le Loarer,Maud Toulmonde,Sophie Piperno-Neumann,Carine Bellera,Charles Honore,Jean-Yves Blay,Simone Mathoulin-Pelissier
Background The coronavirus disease 2019 (COVID-19) pandemic was an unprecedented shock to the healthcare systems, and its consequences on managing rare cancers are unknown. We investigated COVID-19's impact on the activity of sarcoma-labeled networks by comparing key indicators in 2019-2020 (before and during the pandemic, respectively). Methods We compared the incidence of limb and trunk soft tissue
-
Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-25 Shun Lu,Xiangqian Zheng,Yuping Sun,Dingzhi Huang,Lin Wu,Qinghai Ji,Chengzhi Zhou,Jianying Zhou,Ye Guo,Minghua Ge,Ding Ding,Jingxin Shao,Wanli Zhang,Ming Gao,Ying Cheng
Background Patient-reported outcomes (PROs) are increasingly becoming an important part of clinical trials as they are helpful in analyzing the safety and efficacy of treatment in chronic diseases like cancer. Objectives We report PROs and health-related quality of life (HRQoL) with selpercatinib treatment among Chinese patients with rearranged in transfection (RET) fusion-positive non-small-cell lung
-
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-24 Daniela Cárdenas-Fernández,Pamela Soberanis Pina,Jenny G Turcott,Norberto Chávez-Tapia,Emilio Conde-Flores,Andrés F Cardona,Oscar Arrieta
The identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung adenocarcinoma has facilitated the development of personalized medicine based on oncogenic drivers. EGFR-Tyrosine Kinase Inhibitors (TKIs) are part of the targeted therapy; they impede the phosphorylation of the intracellular tyrosine kinase component of EGFR and consequently block signal transduction pathways. These drugs
-
The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-24 Saurav Verma,Sympascho Young,Alexander V Louie,David Palma,Daniel Breadner
The improvement in treatment strategies and outcomes in small cell lung cancer (SCLC) has lagged behind other cancers. The addition of immune checkpoint inhibitors (ICIs), durvalumab and atezolizumab, to the platinum-based chemotherapy in frontline setting has improved the survival in extensive stage SCLC, (ES-SCLC), albeit modestly, and is now the new standard of care. Prior to advent of immunotherapy
-
2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-24 César Serrano,Javier Martín-Broto,José Manuel Asencio-Pascual,José Antonio López-Guerrero,Jordi Rubió-Casadevall,Silvia Bagué,Xavier García-Del-Muro,Juan Ángel Fernández-Hernández,Luís Herrero,Antonio López-Pousa,Andrés Poveda,Virginia Martínez-Marín
Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with essentially no metastatic potential to malignant and life-threatening spread diseases. Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases are the crucial drivers of most GISTs, responsible for tumor initiation and evolution
-
A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-18 Lise Verbruggen,Lisa Verheggen,Greetje Vanhoutte,Catherine Loly,Willem Lybaert,Ivan Borbath,Philippe Vergauwe,Koen Hendrickx,Celine Debeuckelaere,Amy de Haar-Holleman,Jean-Luc Van Laethem,Marc Peeters
Background Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due to the lack of clear real-world data on the efficacy of the different regimens, there is no consensus
-
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-11 Mark Pegram,Richard Pietras,Chau T Dang,Rashmi Murthy,Thomas Bachelot,Wolfgang Janni,Priyanka Sharma,Erika Hamilton,Cristina Saura
Breast cancer (BC) with expression of the estrogen receptor (ER) and/or progesterone receptor (PR) protein and with overexpression/amplification of the human epidermal growth factor receptor 2 (HER2), termed hormone receptor-positive (HR+)/HER2+ BC, represents ∼10% of all BCs in the United States. HR+/HER2+ BC includes HER2+ BCs that are ER+, PR+, or both ER+ and PR+ (triple-positive BC). Although
-
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-02 Hui Chen,Qingqing Ding,Laila Khazai,Li Zhao,Senthil Damodaran,Jennifer K Litton,Gaiane M Rauch,Clinton Yam,Jeffrey T Chang,Sahil Seth,Bora Lim,Alastair M Thompson,Elizabeth A Mittendorf,Beatriz Adrada,Kiran Virani,Jason B White,Elizabeth Ravenberg,Xingzhi Song,Rosalind Candelaria,Banu Arun,Naoto T Ueno,Lumarie Santiago,Sadia Saleem,Sausan Abouharb,Rashmi K Murthy,Nuhad Ibrahim,Mark J Routbort,Aysegul
Background Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective To understand the changes in PTEN expression over the course of the disease in patients with triple-negative breast cancer (TNBC) and whether PTEN copy number variation (CNV) by next-generation sequencing (NGS)
-
Immune gene signatures as prognostic criteria for cancer patients. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-02 Irina Larionova,Liubov Tashireva
Recently, the possibility of using immune gene signatures (IGSs) has been considered as a novel prognostic tool for numerous cancer types. State-of-the-art methods of genomic, transcriptomic, and protein analysis have allowed the identification of a number of immune signatures correlated to disease outcome. The major adaptive and innate immune components are the T lymphocytes and macrophages, respectively
-
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going? Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-02 Ning Chen,Xiaoling Xu,Yun Fan
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have
-
Novel radionuclide therapy combinations in prostate cancer. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-02 Andrisha-Jade Inderjeeth,Amir Iravani,Shalini Subramaniam,Ciara Conduit,Shahneen Sandhu
Prostate cancer remains the commonest cancer diagnosed in males and a leading cause of cancer-related death. Men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on chemotherapy and androgen receptor pathway inhibitors (ARPI) have limited treatment options, significant morbidity, and poor outcomes. Prostate-specific membrane antigen (PSMA)-directed radionuclide therapy
-
Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-01 Manon Falette-Puisieux,Jean-Charles Nault,Mohamed Bouattour,Marie Lequoy,Giuliana Amaddeo,Thomas Decaens,Frederic Di Fiore,Sylvain Manfredi,Philippe Merle,Aurore Baron,Christophe Locher,Anna Pellat,Romain Coriat
Background In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives The aim of this retrospective multicenter real-world cohort study was to provide an evaluation of the efficacy and safety of the use of second-line tyrosine kinase inhibitors
-
Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-08-01 Danbee Kang,Juhee Cho,Seri Park,Hyo Jung Kim,Seok Won Kim,Jeong Eon Lee,Jonghan Yu,Se Kyung Lee,Ji-Yeon Kim,Seok Jin Nam,Yeon Hee Park
Background Pretreatment endocrine symptoms in premenopausal patients might be considered as a potential marker of poor prognosis. We conducted a cohort study to evaluate the association between endocrine symptoms prior to treatment and recurrence-free survival (RFS) among premenopausal patients with breast cancer aged ⩽40 years. Methods Data were obtained from a prospective cohort study (NCT03131089)
-
HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-07-29 Milton J Barros,Jonathan Strosberg,Taymeyah Al-Toubah,Victor Hugo F de Jesus,Lais Durant,Celso A Mello,Tiago C Felismino,Louise De Brot,Rodrigo G Taboada,Mauro D Donadio,Rachel P Riechelmann
Background Nearly 30% of neuroendocrine tumors (NETs) have evidence of immunohistochemical (IHC) expression of estrogen (ER) and/or progesterone (PR) receptors. Therefore, targeting ER/PR may offer an effective NET-directed treatment to select patients. Methods We conducted a multicenter Simon two-stage single-arm phase II trial of tamoxifen in patients with metastatic, progressive NETs. Eligible patients
-
Role of perioperative immunotherapy in localized renal cell carcinoma. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-07-29 Jasmeet Kaur,Goutham Patil,Daniel M Geynisman,Pooja Ghatalia
Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being
-
Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-07-29 Ting Deng,Zhigang Liu,Zhengquan Han,Huan Zhou,Rui Liu,Yijing Li,Shaorong Li,Peng Xiu,Shuni Wang,Yiping Zhang,Yi Ba
Background Lymphocyte-activation gene 3 (LAG-3), a checkpoint molecule contributing to immune suppressive microenvironment, is regarded as a promising target in cancer treatment. SHR-1802 is a novel anti-LAG-3 monoclonal antibody. Objectives To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of SHR-1802. Design A phase I dose-escalation and expansion trial of SHR-1802 in
-
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-07-21 Ming-Shen Dai,Ta-Chung Chao,Chang-Fang Chiu,Yen-Shen Lu,Her-Shyong Shiah,Christopher G C A Jackson,Noelyn Hung,Jianguo Zhi,David L Cutler,Rudolf Kwan,Douglas Kramer,Wing-Kai Chan,Albert Qin,Kuan-Chiao Tseng,Cheung Tak Hung,Tsu-Yi Chao
Background Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous form. Encequidar (E) is a first-in-class, minimally absorbed, gut-specific oral P-gp inhibitor that facilitates
-
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther. Adv. Med. Oncol. (IF 4.9) Pub Date : 2023-07-17 Firas Y Kreidieh,Hussein A Tawbi
Despite major advances with immunotherapy and targeted therapy in the past decade, metastatic melanoma continues to be a deadly disease for close to half of all patients. Over the past decade, advancement in immune profiling and a deeper understanding of the immune tumor microenvironment (TME) have enabled the development of novel approaches targeting and a multitude of targets being investigated for